GRAIL is a life sciences company whose mission is to detect cancer early when it can be cured. GRAIL combines the power of high-intensity sequencing (ultra-broad and ultra-deep sequencing), leading-edge computer science, and large population-scale clinical studies to enhance the scientific understanding of cancer biology and develop a blood test for early-stage cancer detection.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/17 | $900,000,000 | Series B |
Amazon.com ARCH Venture Partners  Bristol-Myers Squibb Celgene Corporation Johnson & Johnson Innovation McKesson Ventures Merck Ventures Tencent Holdings Varian Medical Systems | undisclosed |
| 05/07/20 | $390,000,000 | Series D |
Canada Pension Plan Investment Board Illumina, Inc PSP Investments | undisclosed |
